Abstract
Gprotein-coupled receptors (GPCRs) are the most successful class of drug targets to date (1). Almost half of the 500 molecular targets for currently used therapeutic agents are cell surface receptors, and the majority of these belong to the GPCR superfamilies. Of the GPCRs, one of the most important classes in the central nervous system is the metabotropic glutamate receptor family (mGluRs) (see ref. 2 for review). Glutamate is the neurotransmitter at the vast majority of excitatory synapses in the brain, and mGluRs provide a mechanism by which glutamate can modulate or fine tune activity at the same synapses at which it elicits fast synaptic responses through activation of ligand-gated cation channels. Because of the ubiquitous distribution of glutamatergic synapses, mGluRs participate in a wide variety of functions of the CNS (3). However, developing highly selective agonists for specific mGluR subtypes has been exceedingly difficult, likely because of the high conservation of the glutamate-binding site across members of this receptor family and the restricted structural requirements for pharmacophores that occupy this binding pocket. In a recent issue of PNAS, Mitsukawa et al. (4) report an exciting advance in the field by identifying the first highly selective agonist for an mGluR subtype termed mGluR7, a receptor that has long been postulated to be among the most important members of this family in regulating CNS function. The compound described by Mitsukawa et al. (4), called AMN082, was identified by using a random high-throughput screen (HTS) of a library of small drug-like molecules in search of novel compounds that activate this receptor. From this screen and subsequent experiments, AMN082 emerged as a highly selective and potent agonist of mGluR7. In addition to providing the first selective ligand for this important receptor subtype, AMN082 acts by a unique mechanism of action, fully activating mGluR7 through …

This publication has 15 references indexed in Scilit: